COX-2 inhibitors and arterial hypertension: An analysis of spontaneous case reports in the Pharmacovigilance database

European Journal of Clinical Pharmacology

Volumn 61, Issue 8, 2005, Pages 611-614

  Durrieu, G ^a   Olivier, P ^a   Montastruc, J L ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ARTICLE; DATA BASE; DRUG SURVEILLANCE PROGRAM; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; PRIORITY JOURNAL;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DATABASES, FACTUAL; FEMALE; FRANCE; HUMANS; HYPERTENSION; LACTONES; MALE; MIDDLE AGED; ODDS RATIO; PYRAZOLES; SULFONAMIDES; SULFONES;

EID: 26244456607     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0964-z     Document Type: Article

References (17)

1. Pope JE, Anderson JJ, Felson DT (1993) A meta-analysis of the effects of non-steroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153:477-484
2. Jonhson AG, Nguyen TV, Day RO (1994) Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 121:289-300
3. Frishman W (2002) Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol 89(Suppl):18D-25D
4. Amstrong E, Malone D (2003) The impact of non-steroidal anti-inflammatory drugs on blood pressure, with emphasis on newer agents. Clin Ther 25:1-18
5. Edwards I, Aronson J (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255-1260
6. Bégaud B, Evreux JC, Jouglard J, Lagier G (1985) Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Thérapie 40:111-118
7. Whelton A, White W, Bello A, Puma J, Fort J, *the SUCCESS-VII Investigators (2002) Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 90:959-963
8. Zhao S, Reynolds M, Lefkowitz J, Whelthon A, Arellano F (2001) A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World health Organisation/Uppsala Monitoring Centre Safety Database. Clin Ther 23:1478-1491
9. Solomon D, Schneeweiss S, Levin R, Avorn J (2004) Relationship between COX-2 specific inhibitors and hypertension. Hypertension 44:140-145
10. Wolfe F, Zhao S, Reynolds M, Petitt D (2004) Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. J Rheumatol 31:1143-11151
11. Brinker A, Goldkind L, Bonnel R, Beitz J (2004) Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. Drugs Aging 21:479-484
12. Mandani M, Juurlink D, Lee D, Rochon P, Koop A, Naglie G, Austin P (2004) Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363:1751-1756
13. Griffin MR, Stein CM, Graham DJ, Daugherty JR, Arbogast PG, Ray WA (2004) High frequency of use of rofecoxib at greater than recommended doses: cause for concern. Pharmacoepidemiol Drug Saf 13:339-343
14. Bombardier C, Laine L, Reicin A et al (2000) Comparison of upper gastro-intestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis; VIGOR Study Group. N Engl J Med 343:1520-1528
15. Silverstein FE, Faich G, Golstein JL et al (2000) for the Celecoxib Long-term Arthritis Safety Study. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the class study: a randomized controlled trial. JAMA 284:1247-1255
16. Whelton A, Singh G, White W et al (2001) Celecoxib does not increase the risk of cardiac failure, edema, or hypertension compared to NSAIDs: results from SUCCESS 1, a double blind, randomized trial in 13 274 OA patients. In: Program and abstracts of the American College of Rheumatology 65th Annual Scientific Meeting; November 10-15, San Francisco, CA, Abstract
17. Riendeau D, Percival MD, Brideau C et al (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296:558-566